RxDoctor Payments Data

Chinenye Emuwa, MD

Internal Medicine · Lancaster, PANPI 1629233424

Payments from drug & device makers

$1,403in general payments, 2019–2025

Across 31 payments — averaging $45.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$574
  • AstraZeneca$403
  • Harmony Biosciences LLC$141
  • Biohaven Pharmaceutical Holding Company Ltd.$118
  • Boehringer Ingelheim$39
  • Axsome Therapeutics, Inc.$33
  • plus $95 from 4 others

What the payments were for

  • Food & beverage$1,26290%
  • Education$14110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,403 in reported general payments places this provider in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$44,438
Medicare patients
250
Services billed
589

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate24$315,461
Trelegy ElliptaFluticasone/Umeclidin/Vilanter230$157,834
Breztri AerosphereBudesonide/Glycopyr/Formoterol136$88,591
Breo ElliptaFluticasone/Vilanterol125$54,783
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr76$40,214
Spiriva RespimatTiotropium Bromide63$35,671
Incruse ElliptaUmeclidinium Bromide56$20,437
Arnuity ElliptaFluticasone Furoate63$15,124
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate65$14,676
Roflumilast121$11,515
Stiolto RespimatTiotropium Br/Olodaterol Hcl18$9,961
DuleraMometasone/Formoterol28$9,843
Bevespi AerosphereGlycopyrrolate/Formoterol Fum22$8,885
SymbicortBudesonide/Formoterol Fumarate15$6,840
Combivent RespimatIpratropium/Albuterol Sulfate12$6,607

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$39$367,699117 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$574$288,392550 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort$403$104,316173 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Lancaster

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →